Format

Send to

Choose Destination
Leuk Lymphoma. 2015;56(11):3143-9. doi: 10.3109/10428194.2015.1030639. Epub 2015 May 18.

Economic impact of disease progression following front-line therapy in classical Hodgkin lymphoma.

Author information

1
a Willamette Valley Cancer Institute/The US Oncology Network, McKesson Specialty Health , Springfield , OR , USA.
2
b McKesson Specialty Health The Woodlands , TX , USA.
3
c Texas Oncology/The US Oncology Network , Austin , TX , USA.

Abstract

The current study aimed to assess the economic burden of progressive disease among patients with Hodgkin lymphoma (HL) receiving second- or third-line therapy in a large US network of community-based practices. This retrospective, observational cohort analysis used electronic health records to examine adult patients with classical HL who received chemotherapy between 2007 and 2011. Of 291 observations, 112 had non-progressive disease (received only one line of therapy; LOT1), 114 received second-line therapy (LOT2), and 65 received third-line therapy (LOT3). In LOT2, 49 patients (43%) underwent transplant. In LOT3, 13 patients (20%) underwent transplant. The mean total cost per line of therapy was $21 956 in LOT1, $77 219 in LOT2, and $59 442 in LOT3. When transplant was required, the mean total cost per line of therapy increased 7- to 8-fold when compared with the cost of LOT1 (approximately $154 000 for LOT2 and $193 000 for LOT3). Future therapies that intervene as early as possible in the treatment algorithm to prevent or significantly delay relapse will likely result in significant cost savings.

KEYWORDS:

Disease progression; Hodgkin lymphoma; health economics

PMID:
25860233
DOI:
10.3109/10428194.2015.1030639
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center